Shenyang Xingqi Pharmaceutical Co.,Ltd

Shenzhen Stock Exchange 300573.SZ

Shenyang Xingqi Pharmaceutical Co.,Ltd Price to Sales Ratio (P/S) on January 14, 2025: 8.19

Shenyang Xingqi Pharmaceutical Co.,Ltd Price to Sales Ratio (P/S) is 8.19 on January 14, 2025, a -40.26% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Shenyang Xingqi Pharmaceutical Co.,Ltd 52-week high Price to Sales Ratio (P/S) is 24.44 on May 14, 2024, which is 198.32% above the current Price to Sales Ratio (P/S).
Shenyang Xingqi Pharmaceutical Co.,Ltd 52-week low Price to Sales Ratio (P/S) is 7.48 on January 09, 2025, which is -8.68% below the current Price to Sales Ratio (P/S).
Shenyang Xingqi Pharmaceutical Co.,Ltd average Price to Sales Ratio (P/S) for the last 52 weeks is 12.92.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Shenzhen Stock Exchange: 300573.SZ

Shenyang Xingqi Pharmaceutical Co.,Ltd

CEO	Ms. E. Gao
IPO Date	Dec. 9, 2016
Location	China
Headquarters	No. 68, Lishui Street
Employees	1,995
Sector	Health Care
Industries Pharmaceuticals Cosmetics Eyewear

Description

Shenyang Xingqi Pharmaceutical Co., Ltd engages in the research and development, production, and sale of ophthalmic products in China. It offers corneal, anti-bacteria, artificial tears, anti-inflammation, surgical perfusate, mydriactics, anti-fatigue, and pre dry and over dry eye treatment products. The company is based in Shenyang, China.

Key trends

Past 5 years